Renal Cell Carcinoma (eBook)

Ronald M Bukowski MDEmeritus Staff PhysicianCleveland Clinic Taussig Cancer CenterProfessor Emeritus of MedicineCCF Lerner College of Medicine of CWRURobert Figlin MDProfessor of Medicine and Biomedical SciencesDirector, Division of Hematology OncologyDepartment of Medicine, Cedars-Sinai Medical CenterAssociate Director for Academic ProgramsSamuel Oschin Comprehensive Cancer InstituteProfessor Emeritus of Medicine and UrologyDavid Geffen School of Medicine at UCLARobert Motzer MDAttending PhysicianDepartment of MedicineMemorial Sloan-Kettering Cancer CenterProfessor of MedicineWeil Medical College of Cornell University

Table of Contents“Renal Cell Carcinoma: Molecular Targets & Clinical Applications, 3rd Edition”Editors: Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.  Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten YearsRonald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D. Ch. 2: RCC: Pathologic and Molecular assessment of Targets             Ferran Algaba, M.D. Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years            Stephen M. Keefe, M.D., W. Kimryn Rathmell, M.D., Ph.D., Katherine L. Nathanson, M.D. Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications Lucy Gossage, M.R.C.P., M.Sc.  Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling ComplexChung-Han Lee, M.D., Ph.D., Can G. Pham, Ph.D., James J. Hsieh, M.D., Ph.D. Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes Ruhee Dere, Ph.D., Thai H. Ho, M.D., Ph.D. Ch. 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications? Susan A.J. Vaziri, Ph.D, Mahrukh K. Ganapathi, Ph.D, Ram N. Ganapathi, Ph.D. Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results Han Hsi Wong, Ph.D. Tim Eisen, Ph.D., F.R.C.P. Ch. 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status Linda Cerbone, M.D., Cora N. Sternberg, M.D., F.A.C.P.Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity? Hui Zhu, M.D., Ph.D., Brian I. Rini, M.D. F.A.C.P.,  Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC Bernard Escudier, M.D., Laurence Albiges, M.D. Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC Daniel C. Cho, M.D., James W. Mier, M.D. Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma Egbert Oosterwijk, Ph.D., Otto C. Boerman, Ph.D., Jeannette C. Oosterwijk-Wakka, B.Sc. Wim J. Oyen, M.D., Ph.D., Peter F. A. Mulders, M.D., Ph.D. Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma Sarathi Kalra, M.D., Eric Jonasch, M.D. Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell CarcinomaFabiola Cecchi, Ph.D., Young H. Lee, Ph.D., Benedetta Peruzzi, Ph.D., Jean-Baptiste Lattouf, M.D. Donald P. Bottaro, Ph.D. Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance James W. Mier, M.D., Rupal S. Bhatt, M.D., Ph.D., David J. Panka, Ph.D., Michael B. Atkins, M.D. Ch. 17: Development of Combination Therapy with Targeted Agents  C. Lance Cowey, M.D., Thomas E. Hutson, D.O., Pharm.D., F.A.C.P. Ch. 18: Side Effects of Targeted Thearpy Luis Leon, M.D., Luis Miguel Anton Aparicio, M.D., Emilio Esteban Gonzalez, M.D., Martin Lazaro Quintela, Ph.D., Sergio Vazquez Estevez, M.D. Ch. 19: The Role of Targeted Therapy in Special Populations James M.G. Larkin, Ph.D., F.R.C.P., Martin E. Gore, Ph.D., F.R.C.P. Ch. 20: Immunotherapy: the Current Role of Cytokines Mayer Fishman, M.D., Ph.D. Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC David F. McDermott, M.D., Alexandra Bailey, M.D. Ch. 22: Vaccines in RCC: Clinical and Biological Relevance Devin B. Lowe, Ph.D., James H. Finke, Ph.D., Jorge A. Garcia, Walter J. Storkus, M.D. Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics  Sumanta K. Pal, M.D., Robert A. Figlin, M.D. Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma Steven G Koopman, M.D., Ali-Reza Sharif-Afshar, M.D., Robert A Figlin, M.D., Hyung L Kim, M.D.  Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma Nimira Alimohamed M.D., Toni K. Choueiri M.D., Daniel Y.C. Heng M.D.   Ch. 26: The Role of Advocacy in Renal Cell Carcinoma William P. Bro, B.S.B., Paul Larson, M.S.